Republican rise puts Obamacare under more pressureThe outlook for the Obamacare health reforms are once again in doubt following last week’s mid-term elections in Share XRepublican rise puts Obamacare under more pressurehttps://pharmaphorum.com/news/republican-rise-puts-obamacare-under-more-pressure/
Bristol-Myers secures option to buy Danish firm behind inhaled IPF drugBristol-Myers Squibb has secured an exclusive option to acquire Galecto Biotech and gain worldwide rights to its lead Share XBristol-Myers secures option to buy Danish firm behind inhaled IPF drughttps://pharmaphorum.com/news/bristol-myers-secures-option-to-buy-danish-firm-behind-inhaled-ipf-drug/
Financial strain putting NHS at risk warns National Audit OfficeThe financial position of the NHS has worsened since 2012-13, with growing financial stress in NHS trusts and Share XFinancial strain putting NHS at risk warns National Audit Officehttps://pharmaphorum.com/news/financial-strain-putting-nhs-at-risk-warns-national-audit-office/
Spark’s gene therapy gets FDA breakthrough statusSpark Therapeutics has become the first company to get breakthrough status from the US Food and Drug Administration Share XSpark’s gene therapy gets FDA breakthrough statushttps://pharmaphorum.com/news/sparks-gene-therapy-gets-fda-breakthrough-status/
Growth strengthens AZ against PfizerAstraZeneca (AZ) CEO Pascal Soriot’s push towards ambitious revenue targets seems to be paying off, with the company Share XGrowth strengthens AZ against Pfizerhttps://pharmaphorum.com/news/growth-strengthens-az-against-pfizer/
Sarepta’s stumble puts Prosensa in front for DMD therapySarepta confirmed yesterday it will file its Duchenne muscular dystrophy (DMD) drug eteplirsen in mid-2015 in the US, Share XSarepta’s stumble puts Prosensa in front for DMD therapyhttps://pharmaphorum.com/news/sareptas-stumble-puts-prosensa-in-front-for-dmd-therapy/
Lilly gains new stomach cancer approval for CyramzaThe FDA has said Lilly’s new stomach cancer drug Cyramza can be given alongside paclitaxel, extending its earlier Share XLilly gains new stomach cancer approval for Cyramzahttps://pharmaphorum.com/news/lilly-gains-new-stomach-cancer-approval-for-cyramza/
Vertex’s future riding on CF combinationA new two-drug combination to treat cystic fibrosis has been filed in Europe and the US by Vertex, Share XVertex’s future riding on CF combinationhttps://pharmaphorum.com/news/vertexs-future-riding-on-cf-combination/
Arzerra gains NICE nod – but Imbruvica is waiting in the wingsGlaxoSmithKline has secured NICE approval for Arzerra, its chronic lymphocytic leukaemia (CLL) treatment – with a little help Share XArzerra gains NICE nod – but Imbruvica is waiting in the wingshttps://pharmaphorum.com/news/arzerra-gains-nice-nod-but-imbruvica-is-waiting-in-the-wings/
